Effective Test For Cervical Cancer Screening

Effective Test For Cervical Cancer Screening.
An HPV examine recently approved by US fitness officials is an effective way to check for cervical cancer, two outstanding women's health organizations said Thursday. The groups said the HPV exam is an effective, one-test alternative to the current recommendation of screening with either a Pap examination alone or a combination of the HPV test and a Pap test. However, not all experts are in agreement with the move: the largest ob-gyn alliance in the United States, the American College of Obstetricians and Gynecologists (ACOG) is still recommending that women grey 30 to 65 be screened using either the Pap test alone, or "co-tested" with a coalition of both the HPV test and a Pap test. The new, so-called interim auspices report was issued by two other groups - the Society of Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology.

It followed US Food and Drug Administration authorization last year of the cobas HPV probe as a primary test for cervical cancer screening. The HPV try detects DNA from 14 types of HPV - a sexually transmitted virus that includes types 16 and 18, which cause 70 percent of cervical cancers. The two medical groups said the interim regulation make public will help health care providers draw how best to include primary HPV testing in the care of their female patients until a number of medical societies update their guidelines for cervical cancer screening.

And "Our examination of the data indicates that leading HPV testing misses less pre-cancer and cancer than cytology a Pap test alone. The government panel felt that primary HPV screening can be considered as an option for women being screened for cervical cancer," interim direction report lead author Dr Warner Huh said in a newsflash release from the Society of Gynecologic Oncology. Huh is director of the University of Alabama's Division of Gynecologic Oncology The FDA approved the cobas HPV assay continue April as a first step in cervical cancer screening for women aged 25 and older.

Roche Molecular Systems Inc, headquartered in Pleasanton, California, makes the test. Thursday's interim communication recommends that fundamental HPV testing should be considered starting at age 25. For women younger than 25, tendency guidelines recommending a Pap test solo beginning at age 21 should be followed. The new recommendations also state that women with a negative development for a primary HPV test should not be tested again for three years, which is the same interval recommended for a normal Pap check result.